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with activating EGFR gene mutations: 
the Okayama Lung Cancer Study Group 
Trial 1001.” In this clinical trial, the 
authors assessed the efficacy of beva-
cizumab and gefitinib combination 
therapy in non–small-cell lung cancer 
(NSCLC) and proposed the promis-
ing conclusion that the combination 
therapy of bevacizumab and gefitinib is 
favorable. Although the study provided 
promising findings on the combination 
treatment for NSCLC, several latest 
findings should be further discussed and 
emphasized.
First, the tolerability of bevaci-
zumab among the elderly has caused 
a wide controversy. A recent trial con-
ducted by Bakogeorgos et al.2 validates 
the poor compliance and toxicity of 
elderly patients whose age is up to 70 
years in the first-line therapy. The results 
indicate that elderly patients were less 
likely to receive bevacizumab (7.5% 
versus 21.3%) compared with the non-
elderly patients. The trial reveals that 
elderly patients with NSCLC may have 
treatment disadvantages compared with 
younger counterparts in these trials. 
Similar result was also presented by the 
Eastern Cooperative Oncology Group 
4599 and PointBreak trials,3 in which 
patients aged up to 74 years have no 
more benefit than younger patients with 
the addition of bevacizumab and encoun-
ter severe adverse events. The poor toler-
ability is possible due to elderly people’s 
slow metabolite rate and poor compli-
ance. Consequently, the dosage and eli-
gibility criteria should be arranged to fit 
the elderly patient’s condition.
Second, the cost-effectiveness is 
an important component for economic 
evaluation in the future treatment. 
According to a systematic review,3 
bevacizumab has an incremental cost- 
effectiveness ratios (ICERs) greater 
than $150,000 per quality-adjusted 
life-year (QALY). In epidermal growth 
factor receptor–mutated advanced 
NSCLC, testing available tissue for 
target therapy can yield an ICER of 
$110,644 per QALY, and the rebiopsy 
yields an ICER of $122,219 per QALY. 
Gefitinib had an ICER of $19,214 
per QALY. However, recent clinical 
NSCLC guidelines were based on no 
cost-effective strategies. The treat-







investigator to know if the scope of their 
research or data analysis output over-
laps. It is highly unlikely that genomic 
researchers investigating somatic tumor 
mutations would find a situation where 
contacting a patient’s physician would 
be called for, this type of research most 
often uses archived specimens at a time 
point well past when the information 
would be of use to strategizing treat-
ment. However, for research that covers 
hereditary factors or more specifically 
established risk variants using DNA 
from a noncancer tissue source, the 
original consent or a follow-up letter 
should ask if the consenting individual 
or members of their family choose to 
be informed in the event of a clinically 
meaningful finding. Then, a reason-
able follow-up to identifying an action-
able variant in the course of a research 
project would be to recommend that a 
patient specimen be retested in the set-
ting of an accredited clinical laboratory 
that offers the test and genetic counsel-
ing as to the meaning of the results.
Aliccia Bollig-Fischer, PhD
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To the Editor:
I commend Ichihara et al.1 for 
their excellent article entitled “Phase 
II trial of gefitinib in combination with 
bevacizumab as first-line therapy for 
advanced non–small cell lung cancer 
specific due to particular histological 
subtypes and different genetic muta-
tions. Therefore, it is essential to con-
duct a further evaluation to define an 
acceptable cost-effectiveness standard 
of bevacizumab or gefitinib, in different 
region for patients with NSCLC.
Finally, although the use of beva-
cizumab may have an effective influence 
in combination with gefitinib, recur-
rence is frequently occurred. Food and 
Drug Administration has abrogated bev-
acizumab in the breast cancer, because 
of lacking the solid proof of increasing 
survival rates.5 According to a recent 
study conducted by Schwaederlé et al.,6 
TP53 mutations are associated with 
higher vascular endothelial growth 
factor-A expression, which is a func-
tional target of bevacizumab. In this 
case, bevacizumab treatment may have 
more chance to reduce the recurrence 
due to the TP53 mutations. What exact 
medication should bevacizumab to 
combine with to overcome the recur-
rence? Future studies need to focus on 
identifying predictive biomarkers of 
recurrence and design targeted thera-
pies based on these findings.
Xiaoshen Zhang, MD
Tongji University Cancer Institute 
Tongji University School of Medicine
Shanghai, China 
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In Response:
We thank Dr. Zhang for his 
thoughtful comments on our arti-
cle, “Phase II Trial of Gefitinib in 
Combination with Bevacizumab as 
First-Line Therapy for Advanced Non–
Small Cell Lung Cancer with Activating 
EGFR Gene Mutations: The Okayama 
Lung Cancer Study Group Trial 1001.” 
He raised some important issues about 
bevacizumab (bev) and gefitinib combi-
nation therapy.
Dr. Zhang referred to recent arti-
cles investigating combination therapies 
containing bev in elderly patients1 and 
questioned its tolerability and benefit. 
Both of the articles he cited focus on bev 
in combination with cytotoxic agents, 
showing less efficacy and more toxicity 
in elderly patients. Although the data on 
bev in combination with cytotoxic agents 
for elderly patients are controversial to 
an extent, it seems to be less beneficial 
and more toxic. However, we should 
consider the combination of bev with 
molecular targeted agents such as erlo-
tinib or gefitinib separately because their 
magnitudes of efficacy and toxicologi-
cal profiles differ from cytotoxic agents. 
There is no evidence of higher toxicity 
in elderly patients treated with bev and 
erlotinib or gefitinib. Furthermore, even 
elderly patients with epidermal growth 
factor receptor (EGFR)-mutated lung 
cancers had greater benefit when treated 
with bev in combination with erlotinib.2 
We agree that elderly patients should 
be followed very carefully during treat-
ment, even when bev is combined with 
a molecular targeted agent such as gefi-
tinib or erlotinib, because of their slower 
metabolism, poorer performance status, 
and increased comorbidities, potentially 
leading to greater toxicity.
Regarding cost-effectiveness, 
we agree that economic evaluation is 
essential when developing a new cancer 
treatment as the cost of pharmacologi-
cal cancer therapy is increasing at an 
incredible pace. As Dr. Zhang men-
tioned, an incremental cost-effective-
ness ratio (ICER) per quality-adjusted 
life-year (QALY) gained is often used 
to evaluate cost efficacy and an ICER 
per QALY of less than a certain value 
(£20,000 in the United Kingdom and 
$50,000 in the United States) is gen-
erally considered as cost effective. 
However, calculating the ICER itself 
has potential problems3: difficulty in 
determining such a threshold based 
on evidence; uncertainty in measuring 
utility values; and a tendency to obtain 
a lower QALY in elderly or sicker 
patients with lower expectation of life. 
We should not only include a cost-effi-
cacy parameter in clinical trials but also 
need to have a broad discussion about 
how it should be evaluated.
Finally, we agree with Dr. 
Zhang’s suggestion that it is neces-
sary to identify predictive biomark-
ers of acquired resistance to bev and 
gefitinib. In addition, we need to know 
which mechanisms cause resistance 
to a combination of bev and gefitinib, 
those of bev resistance (angiogenic 
pathways other than the vascular epi-
dermal growth factor pathway4), those 
of gefitinib resistance (secondary 
EGFR T790M mutation, MET ampli-
fication, etc.5), or other yet undefined 
mechanisms. Given that gefitinib itself 
can inhibit EGFR-mutated lung can-
cers, it is unlikely that just bev-resistant 
mechanisms will induce resistance to a 
combination of bev and gefitinib. If bev 
and gefitinib resistance is caused by the 
same mechanisms as those of gefitinib 
resistance, it might be potentially ben-
eficial to continue bev in subsequent 
therapies because the tumors might not 
be resistant to bev itself.
Eiki Ichihara, PhD, MD
Katsuyuki Hotta, PhD, MD
Katsuyuki Kiura, PhD, MD
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To the Editor:
Rare epidermal growth factor 
receptor (EGFR) mutations in non–
small-cell lung cancer have been fre-
quently reported in the last decade. A 
high incidence and large variety have 
been identified in several cohorts.1 
Notably, clinical characteristics and 
